Acne vulgaris is the most prevalent dermatological condition worldwide, affecting up to 85% of adolescents and a significant proportion of adults. The condition spans a wide severity spectrum, from comedonal lesions to nodulocystic disease carrying long-term scarring risk. Treatment decisions increasingly weigh systemic agents, hormonal therapy, and novel biologics against established topical regimens.
Paroxetine's Mechanism in Rosacea: Serotonin Pathway Clues
Paroxetine, a selective serotonin reuptake inhibitor, may modulate neurovascular dysregulation in rosacea via serotonin pathway interactions.
FDA Approves Skinvive for Facial Wrinkles, Including 'Tech Neck' Lines
The FDA has approved Skinvive, an injectable hyaluronic acid gel, for improving skin smoothness and reducing facial wrinkles, including those on the neck.
FDA Approves First New Sunscreen Active Ingredient in Two Decades
The FDA has approved a new sunscreen active ingredient, bemotrizinol, marking the first such approval in over 20 years. This offers a new option for broad-spectrum UV protection.
FDA's Hormone Therapy Decision: Implications for Aging Skin
The FDA's recent decision regarding hormone therapy for menopausal symptoms has implications for skin aging, a common patient concern.
FDA Approves OTC Switch for Topical Adapalene 0.1% Gel
The FDA has approved the first over-the-counter retinoid, adapalene 0.1% gel, for acne treatment, expanding access to a previously prescription-only therapy.